Author

Mariam Aguas

IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION
IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION

Mariam Aguas  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

Mariam Aguas  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Mariam Aguas  et al.

IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

Mariam Aguas  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Mariam Aguas  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Mariam Aguas  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Mariam Aguas  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

Mariam Aguas  et al.

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT
LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

Mariam Aguas  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Mariam Aguas  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Mariam Aguas  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Mariam Aguas  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Mariam Aguas  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

Mariam Aguas  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Mariam Aguas  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

Mariam Aguas  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

Mariam Aguas  et al.

Item 1 - 17 / 17
1